Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00895817|
Recruitment Status : Completed
First Posted : May 8, 2009
Results First Posted : March 12, 2013
Last Update Posted : March 12, 2013
The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis (EE). EE is an increasingly recognized disorder that has been associated with dysphagia and food impaction. The presence of anatomical abnormalities in the esophagus such as longitudinal furrows, corrugated rings and a narrow caliber esophagus with friable mucosa are classic endoscopic findings. Diagnosis is established with the histologic finding of large numbers (> 15) of eosinophils per high power field. The underlying pathologic mechanism remains poorly understood but food allergies and aeroallergens have been implicated. It is well known that gastroesophageal reflux disease (GERD) may cause esophageal eosinophilia, but it is unclear whether a complex relationship exists between GERD and EE, as recent data suggests. Furthermore, a large number of patients with clinical presentations and endoscopic findings highly suggestive of EE which is confirmed on histology are responding favorably to proton pump inhibitors.
The aims of the study are to (1) compare the clinical efficacy of aerosolized swallowed Fluticasone to Esomeprazole for the treatment of eosinophilic esophagitis, (2) determine whether proton pump inhibitors are effective in the treatment of eosinophilic esophagitis, (3) determine the number of patients with eosinophilic esophagitis that have coexisting gastroesophageal reflux disease, and (4) correlate change in eosinophil count to improvement in symptoms before and after therapy.
|Condition or disease||Intervention/treatment||Phase|
|Eosinophilic Esophagitis||Drug: Swallowed fluticasone Drug: Esomeprazole||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||42 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||October 2010|
|Active Comparator: Swallowed fluticasone||
Drug: Swallowed fluticasone
440 µg twice daily for 8 weeks
|Active Comparator: Esomeprazole||
40 mg once daily for 8 weeks
- Number of Participants Who Responded [ Time Frame: 8 weeks ]Histologic resolution of esophageal eosinophilia. Response is defined as achieving < 7 eosinophils/high power field in both the proximal and distal esophagus.
- Symptom Score [ Time Frame: 8 weeks ]Using a validated questionnaire, symptoms will be assessed at baseline and following therapy.
- Endoscopic Change [ Time Frame: 8 weeks ]Following therapy, resolution of EE findings will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00895817
|United States, District of Columbia|
|Walter Reed Army Medical Center|
|Washington, District of Columbia, United States, 20307|
|Principal Investigator:||Fouad J Moawad, M.D.||Walter Reed Army Medical Center|